The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
about
How the immune system talks to itself: the varied role of synapsesNovel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityAffinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MiceSHP-1 phosphatase activity counteracts increased T cell receptor affinity.Public T cell receptors confer high-avidity CD4 responses to HIV controllersCoreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.Cellular-level versus receptor-level response threshold hierarchies in T-cell activation.Structure-Based, Rational Design of T Cell Receptors.Functional role of T-cell receptor nanoclusters in signal initiation and antigen discriminationCatch Bonds at T Cell Interfaces: Impact of Surface Reorganization and Membrane Fluctuations.Mechanosensing drives acuity of αβ T-cell recognition.Coreceptor scanning by the T cell receptor provides a mechanism for T cell tolerance.Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.Using the force to find the peptides you're looking for.αβ T Cell Receptor Mechanosensing Forces out Serial EngagementCAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma
P2860
Q34320311-94D9BD0C-B9D6-43A6-A190-BA08838B7E4CQ35745453-6F07D2F7-364F-460F-BAC5-EA8838B3B286Q36028047-7A7A35CE-E620-474F-82EC-99E90F23ABC3Q36638160-2D4D8DEE-DF76-4079-B336-8152D0BC2BEEQ36951735-B79EC0B2-3625-4492-A4DA-B58609A3E92AQ37125754-1EA12C4B-039E-4B91-B773-E2A7DE0AE832Q37148101-0E518DA0-8806-4E54-A0CB-2B58C5DD6CB1Q37165240-06BAC2F6-2685-4ACA-9760-46C792413E53Q37264253-BCE1D771-CFCC-4A08-B410-B03CEEB934DEQ38682295-60EDD7E4-05F5-430A-B45B-DEE705121D29Q40092104-648C5F18-6AF6-4131-9384-FC840C5B9AE1Q41715654-C1AABBD1-03A5-41B0-860A-429182C5BDDFQ43448245-3C1B641A-AD24-45C2-809D-C0C49705D8C6Q47127214-9C49FE4F-6C3F-43B5-9A1F-62997887E7A2Q48053700-39983D40-E12C-4365-AF12-3A2D5DE9638BQ56884990-5FE1B87B-156A-4EA9-9061-B9641D42FB3BQ56966447-3D24A7AF-1198-4C17-BC66-A3BE985704A5
P2860
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@en
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@nl
type
label
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@en
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@nl
prefLabel
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@en
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@nl
P2860
P356
P1476
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy.
@en
P2860
P356
10.3389/FIMMU.2012.00272
P577
2012-08-28T00:00:00Z